Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response

Annals of Surgical Oncology

Volumn 14, Issue 7, 2007, Pages 2150-2158

  Tzeng, Ching Wei D ^a   Frolov, Andrey ^a   Frolova, Natalya ^b   Jhala, Nirag C ^b   Howard, J Harrison ^a   Vickers, Selwyn M ^c   Buchsbaum, Donald J ^d   Heslin, Martin J ^a   Arnoletti, J Pablo ^a  

^a Kentucky   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d The University of Alabama at Birmingham   (United States)

Author keywords

EGFR; Epidermal growth factor receptor; Erlotinib; Intron 1; Pancreatic cancer; Polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; PROTEIN KINASE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORRELATION FUNCTION; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRON; MALE; MICRODISSECTION; PANCREAS CANCER; PARAMETER; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SPECTROSCOPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; FEMALE; GENES, ERBB-1; HUMANS; INTRONS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34250828460     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9409-5     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2):106-30
2. Friess H, Wang L, Zhu Z, et al. Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann Surg 1999;230(6):767-74; discussion 74-5
3. Moore M, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Proc Am Soc Clin Oncol 2005 2005; p. 24
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
5. Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006;12(14 Pt 1):4283-7
6. Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006;448(6):788-96
7. Tzeng C, Frolov A, Frolova N, et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 2007;141(4):464-9
8. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64(24):9139-43
9. Etienne-Grimaldi MC, Pereira S, Magne N, et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 2005;16(6):934-41
10. Buerger H, Gebhardt F, Schmidt H, et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60(4):854-7
11. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274(19):13176-80
12. Iwamura T, Katsuki T, Ide K. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 1987;78(1):54-62
13. Simone NL, Remaley AT, Charboneau L, et al. Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. Am J Pathol 2000;156(2):445-52
14. Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2003;2(8):699-709
15. Bor MV, Sorensen BS, Rammer P, Nexo E. Calibrated user-friendly reverse transcriptase-PCR assay: quantitation of epidermal growth factor receptor mRNA. Clin Chem 1998;44(6 Pt 1):1154-60
16. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244(1):10-5
17. Liu W, Innocenti F, Chen P, Das S, Cook EH Jr, Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9(3):1009-12
18. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33(4):369-85
19. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12(24):7242-51
20. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006;12(21):6326-30
21. Richter M, Zhang H. Receptor-targeted cancer therapy. DNA Cell Biol 2005;24(5):271-82
22. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24(31):5034-42
23. Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006;13(6):823-35
24. Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005;41(3):453-60
25. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23(11):2445-59
26. Haley J, Whittle N, Bennet P, Kinchington D, Ullrich A, Waterfield M. The human EGF receptor gene: structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1987;1(4):375-96
27. Haley JD, Waterfield MD. Contributory effects of de novo transcription and premature transcript termination in the regulation of human epidermal growth factor receptor proto-oncogene RNA synthesis. J Biol Chem 1991;266(3):1746-53
28. Gebhardt F, Burger H, Brandt B. Modulation of EGFR gene transcription by a polymorphic repetitive sequence-a link between genetics and epigenetics. Int J Biol Markers 2000;15(1):105-10
29. Zhang W, Gordon M, Press OA, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006;16(7):475-83
30. Zhang W, Stoehlmacher J, Park DJ, et al. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005;5(2):124-31
31. Zhang W, Park DJ, Lu B, et al. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 2005;11(2 Pt 1):600-5
32. Longnecker DS, Karagas MR, Tosteson TD, Mott LA. Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in Asians, blacks, and whites in the United States. Pancreas 2000;21(4):338-43
33. Weinstein I. Cancer Cell Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297(5578):63-4